156143-00-9

Basic information

• Product Name: (S)-(+)-2-(4'-bromophenyl)propanoic acid
• Synonyms: (S)-(+)-2-(4'-bromophenyl)propanoic acid
• CAS NO: 156143-00-9
• Molecular Weight: 229.073
• Mol File: 156143-00-9.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: (S)-(+)-2-(4'-bromophenyl)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(+)-2-(4'-bromophenyl)propanoic acid(156143-00-9)
• EPA Substance Registry System: (S)-(+)-2-(4'-bromophenyl)propanoic acid(156143-00-9)

Safety Data

• Hazardous Substances Data: 156143-00-9(Hazardous Substances Data)

Usage

Description

(S)-(+)-2-(4'-bromophenyl)propanoic acid, commonly known as ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID) characterized by its ability to alleviate pain, reduce fever, and mitigate inflammation. It operates through the inhibition of prostaglandin production, which are the chemicals responsible for inducing pain, fever, and inflammation within the body.

Uses

Used in Pharmaceutical Industry:
Ibuprofen is utilized as an analgesic, antipyretic, and anti-inflammatory agent for the treatment of various conditions such as headaches, muscle aches, arthritis, and menstrual cramps. Its effectiveness in these areas is attributed to its ability to inhibit prostaglandin synthesis, thereby reducing the sensations of pain and fever, as well as inflammation.
Used in Over-the-counter Medications:
Ibuprofen is a key component in numerous over-the-counter (OTC) medications due to its safety and efficacy when used as directed. It is available in different forms, including tablets, capsules, and suspensions, making it accessible and convenient for consumers seeking relief from pain, fever, and inflammation.
Used in Healthcare:
Under the guidance of healthcare professionals, ibuprofen is prescribed to manage pain and inflammation associated with a range of conditions. Its cautious use is emphasized to avoid potential side effects such as gastrointestinal bleeding and kidney damage, which can arise from prolonged use or misuse.

Upstream product

• 64-18-6 formic acid 
• 766-96-1 4-bromo-1-ethynylbenzene 
• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 201230-82-2 carbon monoxide 
• 53086-53-6 2-(4-bromophenyl)propionic acid 
• 80909-78-0 p-bromo-α-methylstyrene oxide 
• 99-90-1 para-bromoacetophenone 
• 40460-91-1 2-(4-bromophenyl)propanal 
• 204851-47-8 (4S)-4-benzyl-3-(2-(4-bromophenyl)acetyl)oxazolidin-2-one 
• 37859-24-8 2-(4-bromophenyl)acetyl chloride 
• 156143-01-0 (1R)-1-phenylethanaminium (2S)-2-(4-bromophenyl)propanoate 
• 847359-07-3 (1S)-2-ethoxy-1-methyl-2-oxoethyl (2S)-2-(4-bromophenyl)propanoate 
• 42186-06-1 2-(4-Bromophenyl)propionitrile 

Downstream Products

• 211315-54-7 (S)-4-benzyl-3-((S)-2-(4-bromophenyl)propanoyl)oxazolidin-2-one 
• 1217864-24-8 C₉H₁₀BrNO 
• 156143-01-0 (1R)-1-phenylethanaminium (2S)-2-(4-bromophenyl)propanoate 
• 156143-26-9 (S)-(+)-tropan-3-yl 2-(4'-bromophenyl)propionate 

Relevant articles and documents

Enantioselective Synthesis of Chiral Carboxylic Acids from Alkynes and Formic Acid by Nickel-Catalyzed Cascade Reactions: Facile Synthesis of Profens

We report a stereoselective conversion of terminal alkynes to α-chiral carboxylic acids using a nickel-catalyzed domino hydrocarboxylation-transfer hydrogenation reaction. A simple nickel/BenzP* catalyst displayed high activity in both steps of regioselective hydrocarboxylation of alkynes and subsequent asymmetric transfer hydrogenation. The reaction was successfully applied in enantioselective preparation of three nonsteroidal anti-inflammatory profens (>90 % ees) and the chiral fragment of AZD2716.

SUBSTITUTED 5-CYCLOPROPYL-1H-PYRAZOL-3-YL-AMINE DERIVATIVES AS SELECTIVE CDK12/13 INHIBITORS

The present invention provides 5-cyclopropyl-1H-pyrazol-3-yl-amine derivatives of formula (I), which are therapeutically useful as selective CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders as

Atropisomer Control in Macrocyclic Factor VIIa Inhibitors

Incorporation of a methyl group onto a macrocyclic FVIIa inhibitor improves potency 10-fold but is accompanied by atropisomerism due to restricted bond rotation in the macrocyclic structure, as demonstrated by NMR studies. We designed a conformational constraint favoring the desired atropisomer in which this methyl group interacts with the S2 pocket of FVIIa. A macrocyclic inhibitor incorporating this constraint was prepared and demonstrated by NMR to reside predominantly in the desired conformation. This modification improved potency 180-fold relative to the unsubstituted, racemic macrocycle and improved selectivity. An X-ray crystal structure of a closely related analogue in the FVIIa active site was obtained and matches the NMR and modeled conformations, confirming that this conformational constraint does indeed direct the methyl group into the S2 pocket as designed. The resulting rationally designed, conformationally stable template enables further optimization of these macrocyclic inhibitors.